Pancreatic Cancer Research

ResearcherRoswell Park Comprehensive Cancer CenterActive in the last 2 years

Thomas A. Mace

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-1070-6819; OpenAlex author ID A5003348560. Sources: OpenAlex.

Their work

Papers
21 (first author 3, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
68
Papers, trials and grants by year

2013: 4 papers · 2014: 1 paper · 2015: 3 papers · 2016: 3 papers · 2017: 1 paper · 2018: 3 papers · 2019: 2 papers · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 21

  1. A Novel Mouse Model to Identify Antigen-Specific Immune Responses in Pancreatic Cancer Cachexia. Last author DOI 10.3390/cancers18040587↗
  2. Physical Activity Decreases Inflammation and Delays the Development of Obesity-Associated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-23-1045↗
  3. Tomatidine targets ATF4-dependent signaling and induces ferroptosis to limit pancreatic cancer progression. Last author DOI 10.1016/j.isci.2023.107408↗
  4. The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer. Last author DOI 10.3390/ijms23137066↗
  5. Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.11.002↗
  6. Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains. Co-author DOI 10.1371/journal.pone.0226714↗
  7. Pancreatic Cancer-Induced Cachexia and Relevant Mouse Models. Last author DOI 10.1097/mpa.0000000000001124↗
  8. Standard Operating Procedures for Biospecimen Collection, Processing, and Storage: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pan… Co-author DOI 10.1097/mpa.0000000000001171↗
  9. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2016-311585↗
  10. Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. Co-author DOI 10.1158/0008-5472.can-16-1986↗
  11. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1038/mt.2016.66↗
  12. Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-15-1732↗
  13. Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5. First author DOI 10.1186/s40425-016-0136-y↗
  14. Anti-IL-6 and PD-L1 antibody combination therapy reduces tumor progression in murine models of pancreatic cancer Co-author DOI 10.1186/2051-1426-3-s2-p366↗
  15. Immunological predictors of overall survival in treatment naïve metastatic pancreatic cancer patients First author DOI 10.1186/2051-1426-3-s2-p85↗
  16. Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer. Co-author DOI 10.18632/oncotarget.6332↗
  17. BMS-911543 inhibits viability of tumor and stromal cells and limits disease progression in genetically engineered mice with pancreatic cancer Co-author DOI 10.1186/2051-1426-2-s3-p186↗
  18. Hypoxia induces the overexpression of microRNA-21 in pancreatic cancer cells. Co-author DOI 10.1016/j.jss.2013.04.061↗
  19. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Co-author DOI 10.1158/0008-5472.can-12-4601↗
  20. Genetically engineered murine pancreatic cancer models approximate immunophenotypic properties of human patients Co-author DOI 10.1186/2051-1426-1-s1-p163↗
  21. Pancreatic cancer-associated stellate cells: A viable target for reducing immunosuppression in the tumor microenvironment. Co-author DOI 10.4161/onci.24891↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gregory B. Lesinski · 14 shared papers, 2013–2019 · strength 0.68
  2. Tanios Bekaii‐Saab · 11 shared papers, 2013–2019 · strength 0.52
  3. Zobeida Cruz‐Monserrate · 6 shared papers, 2017–2024 · strength 0.51
  4. Mark Bloomston · 9 shared papers, 2013–2019 · strength 0.43
  5. Mitch A. Phelps · 3 shared papers, 2013–2026 · strength 0.38
  6. Debasmita Mukherjee · 2 shared papers, 2023–2026 · strength 0.37
  7. Justin W. Thomas · 2 shared papers, 2022–2026 · strength 0.34
  8. Thomas Ludwig · 6 shared papers, 2013–2019 · strength 0.32
  9. Matthew R. Farren · 5 shared papers, 2015–2019 · strength 0.27
  10. Jason Robert Pitarresi · 4 shared papers, 2015–2019 · strength 0.25
  11. Ayushi Das · 1 shared paper, 2026 · strength 0.22
  12. Andrew J. Gunderson · 1 shared paper, 2026 · strength 0.22
  13. Daniel H. Ahn · 4 shared papers, 2015–2019 · strength 0.22
  14. Anne M. Noonan · 4 shared papers, 2015–2019 · strength 0.22
  15. Mary E. Dillhoff · 2 shared papers, 2019–2022 · strength 0.19
  16. Michael C. Ostrowski · 4 shared papers, 2013–2018 · strength 0.19
  17. Karen M. Basen-Engquist · 1 shared paper, 2024 · strength 0.15
  18. Hsiang‐Yin Hsueh · 1 shared paper, 2024 · strength 0.15
  19. Valentina Pita-Grisanti · 1 shared paper, 2024 · strength 0.15
  20. Wei Huang · 1 shared paper, 2024 · strength 0.15
  21. Kristyn Gumpper · 1 shared paper, 2024 · strength 0.15
  22. Ericka Vélez-Bonet · 1 shared paper, 2024 · strength 0.15
  23. Christina Sing-Ying Wu · 3 shared papers, 2015–2016 · strength 0.14
  24. Timothy L. Frankel · 1 shared paper, 2023 · strength 0.14
  25. Sally E. Henderson · 1 shared paper, 2018 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.